Back to List View Graph View

Macrophage

Macrophages are mononuclear phagocytes with two distinct origins: circulating monocytes recruited into tissue, and embryonic and fetal progenitors that seed tissues before birth.

Where the papers sit

16 papers from the last 6 months study macrophage directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 14 preclinical · 2 unclassified

Themes 3 themes · 1 paradigm shift

  • Macrophages in Inflammation and Repair

    Macrophage control is shifting from broad suppression toward restoring efferocytosis, resolution and tissue repair across liver, lung, kidney and wounds. IL-4 programming reduces coronavirus-associated lung inflammation, while GPR91-driven loss of efferocytosis worsens acute liver injury through AC/cAMP/PPARγ signaling. Extracellular vesicles, hydrogels and mannose-targeted particles are being used to redirect inflammatory or fibrotic macrophage states. Whether these approaches consistently prevent fibrosis while preserving antimicrobial defense remains open.

    7 papers · 43.8%

  • Tumor Macrophage Reprogramming

    Tumor macrophages are being treated as drivers of immune suppression and chemotherapy resistance rather than passive bystanders. Spatial profiling repeatedly links CD44- and SPP1-associated states to tumor niches and altered stromal interactions. Nanomedicines, including PI3Kγ-inhibitor liposomes, aim to restore antitumor immunity while improving cisplatin responses. Spatial multi-omics and CRISPR screens are sharpening which macrophage programs and cell contacts should be targeted.

    6 papers · 37.5%

  • Macrophage Ferroptosis in Disease

    Macrophage ferroptosis is emerging as a therapeutic link between lipid injury, atherosclerotic plaques and sepsis. The recurring protective mechanism is NRF2/HO-1/GPX4 control of oxidative lipid damage, while FAR1 identifies a metabolic vulnerability in intestinal macrophages. Repurposed irinotecan and nanomedicine-based delivery broaden the intervention strategies beyond conventional lipid lowering. The key unresolved issue is whether suppressing ferroptosis improves systemic disease without impairing useful inflammatory responses.

    3 papers · 18.8%

PARADIGM SHIFT

Macrophages are not uniformly drivers of tissue injury but can be adaptive effectors of repair

The MASH liver-macrophage study and the mouse full-thickness endometrial-injury regeneration study challenge the set’s prevailing assumption that macrophages are principally inflammatory or tissue-damaging cells. In MASH, infiltrating lipid-associated macrophages are described as an adaptive response that mitigates lipotoxic stress, clears death signals, and supports resolution and fibrosis regression, although chronic exposure can redirect them toward inflammatory and fibrogenic activity 42743990Sep. In endometrial injury, macrophages are indispensable during early regeneration and promote SFRP4-positive stromal-cell reprogramming through TNF-α, thereby enhancing tissue restoration 42234562Jun. The resulting change is a context-dependent account in which macrophages can initiate or enable repair, rather than being treated as intrinsically pathogenic targets for depletion or suppression.

Papers

The 16 papers from the last 6 months that study macrophage directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Macrophages in Inflammation and Repair (7)
  1. Context-Dependent Roles of Liver Macrophages in MASH. Seminars in liver disease · 15 Sept 2026 PMID 42743990
  2. CCL5 mRNA-enriched small extracellular vesicles from renal tubular epithelial cells enhance macrophage inflammatory responses in diabetic nephropathy. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 5 Sept 2026 PMID 42700225
  3. Mannose-modified tobacco mosaic virus-mediated macrophage regulation inhibits pulmonary fibrosis progression. Journal of materials chemistry. B · 3 Aug 2026 PMID 42544440
  4. Adoptive transfer of interleukin-4 programmed macrophages reduces lung inflammation during betacoronavirus infection. International immunopharmacology · 25 Jul 2026 PMID 42501563
  5. Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy. Journal of controlled release : official journal of the Controlled Release Society · 6 Jul 2026 PMID 42409241
  6. Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma. Acta biomaterialia · 2 Jul 2026 PMID 42392517
  7. Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway. Metabolism: clinical and experimental · 23 Jun 2026 PMID 42336269
Tumor Macrophage Reprogramming (6)
  1. Tumor cells recruit macrophage bodyguards to outlast chemotherapy. Cancer cell · 20 Aug 2026 PMID 42624109
  2. pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy. Biomaterials science · 17 Aug 2026 PMID 42605855
  3. Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer. Cell · 5 Aug 2026 PMID 42556334
  4. TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives. Theranostics · 29 Jun 2026 PMID 42370186
  5. Spatial and temporal single cell multi-omics in mice reveals macrophage-SFRP4+ stroma interactions promoting endometrial regeneration via TNF-α. Cell reports · 3 Jun 2026 PMID 42234562
  6. Uncovering spatially resolved functional genomics with CRISPR screen sequencing. Cell · 26 May 2026 PMID 42190664
Macrophage Ferroptosis in Disease (3)
  1. Targeting FAR1 to inhibit intestinal macrophage ferroptosis: repurposing irinotecan as a novel sepsis therapy. Apoptosis : an international journal on programmed cell death · 19 Aug 2026 PMID 42616198
  2. Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine. Journal of applied biomedicine · 23 Jun 2026 PMID 42333862
  3. MCL inhibits macrophage ferroptosis through the NRF2/HO-1/GPX4 axis to attenuate carotid atherosclerotic plaque formation. International immunopharmacology · 22 Jun 2026 PMID 42330582

By study type

Preclinical: animal, cell and lab studies (14)
  1. CCL5 mRNA-enriched small extracellular vesicles from renal tubular epithelial cells enhance macrophage inflammatory responses in diabetic nephropathy. Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 5 Sept 2026 PMID 42700225
  2. Tumor cells recruit macrophage bodyguards to outlast chemotherapy. Cancer cell · 20 Aug 2026 PMID 42624109
  3. Targeting FAR1 to inhibit intestinal macrophage ferroptosis: repurposing irinotecan as a novel sepsis therapy. Apoptosis : an international journal on programmed cell death · 19 Aug 2026 PMID 42616198
  4. pH-Responsive liposomes co-delivering a membrane-active peptide and the PI3Kγ inhibitor to reconstruct the tumor microenvironment for enhanced antitumor immunotherapy. Biomaterials science · 17 Aug 2026 PMID 42605855
  5. Spatial biology reveals altered macrophage states in immunosuppressed non-melanoma skin cancer. Cell · 5 Aug 2026 PMID 42556334
  6. Mannose-modified tobacco mosaic virus-mediated macrophage regulation inhibits pulmonary fibrosis progression. Journal of materials chemistry. B · 3 Aug 2026 PMID 42544440
  7. Adoptive transfer of interleukin-4 programmed macrophages reduces lung inflammation during betacoronavirus infection. International immunopharmacology · 25 Jul 2026 PMID 42501563
  8. Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy. Journal of controlled release : official journal of the Controlled Release Society · 6 Jul 2026 PMID 42409241
  9. Injectable pH-responsive gelatin methacryloyl hydrogel for cuproptosis-synergized sunitinib therapy and immune reprogramming in clear cell renal cell carcinoma. Acta biomaterialia · 2 Jul 2026 PMID 42392517
  10. TAM-targeted nanomedicine in cancer: biological basis, therapeutic strategies, and translational perspectives. Theranostics · 29 Jun 2026 PMID 42370186
  11. Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway. Metabolism: clinical and experimental · 23 Jun 2026 PMID 42336269
  12. Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine. Journal of applied biomedicine · 23 Jun 2026 PMID 42333862
  13. MCL inhibits macrophage ferroptosis through the NRF2/HO-1/GPX4 axis to attenuate carotid atherosclerotic plaque formation. International immunopharmacology · 22 Jun 2026 PMID 42330582
  14. Uncovering spatially resolved functional genomics with CRISPR screen sequencing. Cell · 26 May 2026 PMID 42190664
Unclassified: not yet indexed with MeSH (2)
  1. Context-Dependent Roles of Liver Macrophages in MASH. Seminars in liver disease · 15 Sept 2026 PMID 42743990
  2. Spatial and temporal single cell multi-omics in mice reveals macrophage-SFRP4+ stroma interactions promoting endometrial regeneration via TNF-α. Cell reports · 3 Jun 2026 PMID 42234562